Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 1913954, 1 page
https://doi.org/10.1155/2017/1913954

Corrigendum

Corrigendum to "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E_2 Receptor EP4 Pathway"

Yu Ah Hong,[1] Keum Jin Yang,[2] So Young Jung,[2] Ki Cheol Park,[2] Hyunsu Choi,[2] Jeong Min Oh,[2] Sang Ju Lee,[1] Yoon Kyung Chang,[1] Cheol WheePark,[1] Chul Woo Yang,[1] Suk Young Kim,[1] and Hyeon Seok Hwang[1]

[1]*Division of Nephrology, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea*
[2]*Clinical Research Institute, Daejeon St. Mary's Hospital, Daejeon, Republic of Korea*

Correspondence should be addressed to Hyeon Seok Hwang; hwanghs@catholic.ac.kr

Received 6 June 2017; Accepted 2 July 2017; Published 13 August 2017

In the article titled "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E_2 Receptor EP4 Pathway" [1], an acknowledgement should be added as follows:

The authors also wish to acknowledge the financial support of the Korean Society of Nephrology (JW Pharmaceutical, 2013).

Reference

[1] Y. A. Hong, K. J. Yang, S. Y. Jung et al., "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E_2 Receptor EP4 Pathway," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 5031926, 17 pages, 2017.